Destiny Pharma Share Discussion Threads

[marvelman] 17/1/2024 09:32

Yes, share price seems quite resilient around this area. Surely must be getting very close to the promised update

[someuwin] 17/1/2024 09:23

No buy quote available now.

[marvelman] 17/1/2024 08:37

For those whom have not spotted this,,,,Whilst not trying to plug this (as I am also invested in OBI) it is worth keeping an eye on our other competitor in this market.

[jack jebb] 16/1/2024 13:25

Volume looks pretty insignificant to me, so far.

[carlisle44] 16/1/2024 12:58

Plenty of buying too jeanesy!

[jeanesy] 16/1/2024 09:45

famous last words Jack .. plenty of selling this morning

[jack jebb] 16/1/2024 04:10

The chart looks extremely bullish imo

[brooko19] 15/1/2024 15:43

I wonder when the first milestone payment will land for M3 not suggesting anytime soon but one this year? Be nice when it does like C4XD… on top of everything else happening very exciting times here!

[arab3] 15/1/2024 13:29

Straightjacket , handcuffs and gimp mask coming your way soon xcap !

[supracat] 15/1/2024 13:20

Also expect something re spore gen too as previously intimated we would hear developments and next steps by end of 2023

[xcap1] 15/1/2024 12:57

So we have 2 major announcements 1. Clinical results2. Deal

[xcap1] 15/1/2024 12:56

Arab has restrained me from ramping lol

[arab3] 15/1/2024 11:49

20 % each time if you are lucky !

[mam fach] 15/1/2024 11:42

True. Went back down to 65p which was bit scary.
Luckily it recovered. News can't be very far away now.
Keep holding.

[arab3] 15/1/2024 11:25

Over 80 is when the profit takers probably kick in

[mam fach] 15/1/2024 11:06

Failed to keep over 80p twice which has been disappointing.
Only a positive announcement will move this higher.
But then it will be too late?
Seems to be a little ramping on LSE but it's not having any effect.
GLA

[jeanesy] 15/1/2024 10:45

will it be third time lucky ?

[john henry] 15/1/2024 10:41

Very little stock available under 80p

Approaching Test No3 81-82p this time breaks out aimho

[carlisle44] 15/1/2024 07:43

Capt James T Kirk thanks for sharing.

DP. Fabulous to be in there!

[supracat] 14/1/2024 14:51

Very welcome and totally agree. My hunch is GSK will acquire DP in full or the XF platform globally .....

[captain james t kirk] 14/1/2024 11:33

Within the article is a link to the main report from Persistence Market Research, which is locked but I've extracted this relevant section:

"Which Pathogen holds the highest market share as a causative agent of antibiotic resistance ?

Antibiotic resistance from Staphyloccocus aureus.

In 2022 Staphyloccocus aureus had the greatest market share of 19.5% within the global market.
Stapyloccucus aureus is naturally resistant to almost every antibiotic known to man. Resistance is usually acquired from other sources via horizontal gene transfer, however chromosomal mutation and antibiotic selection are also necessary. Medication resistance in Staphyloccocus aureus can be caused by genetic changes that affect the target DNA gyrase or reduce outer membrane proteins, leading to reduced drug accumulation. As a result Staphyloccocus aureus accounted for the largest share of the market among all pathogens."

So we really could not be better positioned in the fight against antibiotic resistance, particularly when one considers that we also have a drug NTCD-M3 about to enter stage 3 trials in the fight against Clostridium Difficile infections.
It's not hard to see how the XF-73 platform would be of interest to the other 9 global pharma companies on the top 10 list featured in the article. In some cases it would be a great addition to work they are doing on other antibiotic resistant pathogens; such a Roche, for example, who we recently heard are busy developing a new antibiotic to fight A. baumannii infections.
I also note that Astra Zeneca and GSK have been acquiring recently. Let's hope there's still some money left in the kitty.

[jack jebb] 14/1/2024 10:58

thx Capt.

This company is arguably at least 1000% undervalued.

[supracat] 14/1/2024 10:19

Really good to see DP mentioned in the top ten and totally belittles the current market cap, in what is a massive fishing pond which is getting bigger globally by the day. Ty for sharing. I enjoyed reading what was a really good and detailed article on AMR and reinforces what an opportunity DP has worth its XF platform amongst others.